Clinical Trials Browser

OTHER × Recurrence × orelabrutinib × Clear all

NCT04989621 2022-03-24

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Phase 2 Unknown

Lymphoma, Follicular, Recurrence